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http://dx.doi.org/10.1016/j.kjms.201Abstract Fixed-dose combinations (FDCs) are one of the options for improving blood pressure
(BP) goal attainment. We enrolled 141 patients and evaluated the efficacy and safety between
a fixed dose of olmesartan/amlodipine (OA) and a double dose of amlodipine (DA) for treating
mild to moderate hypertension after amlodipine monotherapy failure. After at least 2 weeks
of monotherapy failure, the patients were randomized to receive either OA or DA for 8 weeks.
We compared the systolic blood pressure (SBP)-lowering efficacy of the OA and DA using both
an office BP and an ambulatory blood pressure monitoring (ABPM) device. The intent-to-treat
analysis found that the early (2nd week) and final visit (8th week) SBP reductions were signifi-
cantly greater in those patients receiving OA (n Z 70) than DA (n Z 71) (17.57  15.49 vs.
10.46  13.36 and 24.89  14.09 vs. 17.03  13.27 mmHg, pZ 0.002 and 0.001, respectively).
Among those using ABPM, the patients with 8-week OA had a greater SBP-lowering effect in
comparison with those on DA (14.08 10.74 vs. 6.32 10.21, pZ 0.018). Both treatment strat-
egieswerewell tolerated. This study showed that anOAFDC ismore effective thanDA in reducing
SBP for mild to moderate hypertension after the failure of amlodipine monotherapy.
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.tw (W.-T. Lai).
hsiung Medical University. Published by Elsevier Taiwan LLC. All rights reserved.
2.09.005
266 T.-H. Lin et al.Introduction
disease, gastrointestinal disease or malignancy); and (8)Hypertension is amajor risk factor for cardiovascular disease
[1,2]. Unfortunately, its prevalence is increasing globally.
Antihypertensive agents to decrease blood pressure (BP)
have been shown to be effective in reducing cardiovascular
morbidity and mortality [3]. Several international guidelines
suggest BP treatment goals should be less than 140 mmHg
systolic and 90 mmHg diastolic for uncomplicated hyper-
tension and 130 mmHg systolic and 80 mmHg diastolic for
the high-risk population [4e6]. However, the low rate of
BP goal attainment is a worldwide problem.
Several therapeutic strategies have been proposed to
improve suboptimal BP control. In one study, the
percentage of patients achieving the target BP was signifi-
cantly greater in the combination therapy group than in the
sequential monotherapy and the stepped-care groups [7].
Combination therapy has been suggested in several hyper-
tension treatment guidelines [4e6]. In addition, fixed-dose
combinations (FDCs) can be considered for first-step
treatment, provided the initial use of two drugs rather
than monotherapy is indicated [4,5].
The ACCOMPLISH trial showed that an FDC with
a calcium-channel blocker (CCB) and an angiotensin-
converting enzyme inhibitor (ACEI) has a greater BP-
lowering effect than an FDC with a diuretic and an ACEI
[7]. However, an angiotensin II type 1 receptor blocker
(ARB) has more tolerability than an ACEI, especially in the
Asian population. This study evaluated the efficacy and
safety between an FDC using an ARB and a CCB (olme-
sartan/amlodipine FDC, 20 mg/5 mg) and a double-dose
CCB using amlodipine (10 mg) for the patients with mild
to moderate hypertension not achieving their target BP
after the 5-mg amlodipine monotherapy.Methods
This was an open-label, randomized, multicenter study
comparing the efficacy and safety of an olmesartan/amlo-
dipine FDC (20 mg/5 mg, OA) and a double dose of amlo-
dipine (10 mg, DA) for the treatment of essential
hypertension. This study was conducted at four medical
centers in Taiwan. The study protocol was approved by the
corresponding institutional review boards and applicable
health authorities.Figure 1. Study flowchart.Participant selection
To be included, the participants must have: (1) been
between 20e80 years of age; (2) signed the informed consent
form; (3) received amlodipine 5 mg daily for at least 2 weeks
before the randomization; and (4) recorded a systolic blood
pressure (SBP) between 140 and 180 mmHg or a diastolic BP
(DBP) between 90 and 110 mmHg at both the screening
and randomization visits. Potential participants were
excluded if any of the following were found: (1) secondary
hypertension; (2) pregnancy or breastfeeding; (3) compli-
cated hypertension; (4) chronic renal insufficiency
(creatinine> 2.2 mg/dL); (5) serum potassium> 5.5 mEq/L;
(6) history of a CCB or ARB allergy; (7) other major medicalabnormalities (e.g., severe drug allergy, autoimmune
participation in another investigational drug trial in the 12
weeks before the randomization.
A physical examination and BP measurement were done
at every visit. All BPs were measured with a mercury
sphygmomanometer while the patient was sitting. Two BP
measurements were taken on arrival to the hospital and at
1e2-minute intervals after 10 minutes of rest. The mean BP
was recorded.
Study objective
The primary study objective was to evaluate the difference
in the SBP changes from the baseline to 8weeks between the
two groups. The secondary study objectiveswere to evaluate
the efficacy and safety features via a series of evaluated
parameters including: (1) changes in the sitting SBP from the
baseline to the Week 2 and Week 4 visits; (2) changes in the
DBP from the baseline to the Week 2, Week 4, and Week 8
visits; (3) a successful BP control rate as defined by the
proportion of patients with a final SBP less than 140 mmHg
and a DBP less than 90 mmHg; (4) changes in the 24-hour
mean SBP and DBP from the baseline to theWeek 8 visit [only
for the patients using 24-hour ambulatory blood pressure
monitoring (ABPM)]; and (5) tolerability features including
adverse events and abnormal blood tests.
Patients were randomly assigned to receive either OA
once daily or DA once daily for the 8-week study. We
required a total of five study visits consisting of a screening
visit, randomization visit, evaluation Visit 1 (day 14  3),
evaluation Visit 2 (Day 28  3), and final visit (Day 56  7)
(Fig. 1). A physical examination and BP measurement were
done at every visit. Blood tests were performed at the
randomization visit and final visit. In addition, we recorded
the ABPM on 50% of the total randomized patients based on
a pregenerated randomization list, with the time frame for
the ABPM established on the day of randomization and on
the last day of therapy.
Statistical analysis
All data were expressed as mean  standard error mean
(SEM). All tests were two-sided. A p-value <0.05 was
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rank-sum test were used to compare the categorical data
and nonparametric data, respectively. The student t test
was used for analysis between continuous variables. The
intent-to-treat analysis was used to evaluate the efficacy
and safety. SPSS 11.0 for Windows (SPSS Inc., Chicago, IL,
USA) was used for statistical analysis.
Results
Baseline data
A total of 145 prospective participants were screened; four
failed the screening (3 did not meet the inclusion criteria
and one met the exclusion criteria), and 141 (70 in the OA
and 71 in the DA group) were finally randomized. There was
no statistical significance in the medical compliance
between the OA and DA groups (101.14%  9.47% vs.
98.94%  8.57%, p Z 0.124). The extent of exposure to
drugs was also similar (53.22  10.43 vs. 50.62  14.92 days
for the OA and DA groups, p Z 0.174).
The baseline characteristics are given in Table 1. There
was no difference between the patients taking OA and DA
regarding sex, age, body weight, height, biochemistry data,
and baseline BP.
BP reduction
In the patients taking OA, the SBP decreased 17.57  15.49,
20.80  14.11, and 24.89  14.0 mmHg at 2, 4, and 8
weeks, respectively (Table 2). In the patients taking DA, the
SBP decreased 10.46  13.36, 16.6  17.65, and
17.03  13.27 mmHg at 2, 4, and 8 weeks, respectively.
There was a statistically significant difference in the SBP
reduction between the two groups at Weeks 2 and 8
(p Z 0.002 and 0.001, respectively; Fig. 2A).
The DBP decreased 9.53  9.06, 10.80  9.89, and
12.50  9.78 mmHg in patients taking OA after 2, 4, and 8
weeks of treatment, respectively. In the patients taking DA,
the DBP decreased 5.75  7.72, 9.09  7.76, and
9.29  7.19 mmHg after 2, 4, and 8 weeks’ treatment,
respectively. There was a statistically significant difference
in the DBP reduction between the two groups early in the
study, at the 2nd week (p Z 0.013).Table 1 Baseline characteristics of the study participants.
Characteristics Olmesartan/amlo
70
Age (y) 53.8  10.
Sex (male, %) 64
Weight (kg) 73.5  14.
Height (cm) 164.2  8.2
Fasting sugar (mg/dL) 114.9  7.9
Blood urea nitrogen (mg/dL) 13.1  3.9
Creatinine (mg/dL) 0.84  0.2
Cholesterol (mg/dL) 193.6  31.
Systolic blood pressure (mmHg) 152.4  11.
Diastolic blood pressure (mmHg) 93.6  8.9Among those using ABPM (31 in the OA group and 25 in
the DA group), the patients with 8 weeks of OA had greater
SBP- and DBP-lowering effects compared with those with
DA (14.08  10.74 vs. 6.32  10.2 and 8.62  5.65 vs.
4.27  5.80, p Z 0.018 and 0.011, respectively; Fig. 2B).
After 8 weeks of treatment, a successfully controlled BP
rate (as defined by the proportion of patients with a final
SBP less than 140 mmHg and a DBP less than 90 mmHg) was
achieved in 47 patients (67.1%) and 39 patients (54.9%)
receiving OA and DA, respectively (pZ 0.117). There were
no significant changes in the pulse rate between the two
groups (OA vs. DA, 0.82 vs. e1.12 beats per minute,
p Z 0.678).Safety
Adverse events were defined as treatment related (i.e.,
events that first occurred or worsened after randomiza-
tion). There was no statistically significant difference in the
occurrence of adverse events between the two groups [OA:
28 patients (40%); DA: 31 patients (43.7%), p Z 0.582], nor
between each adverse event (Table 3). Three serious
adverse events were reported (hospitalization for urolith-
iasis, sialolithotomy, and a tumor of the left big toe). The
investigators determined the causality was unrelated or
unlikely to be related to the study medication. As for the
lower-leg edema, 24.3% of the patients who received OA
versus 28.2% of those who received DA had edema at the
randomization visit. There was no statistical significance
for the changes in edema between the two groups after 8
weeks of treatment. The improved/unchanged/worsened
edema statistics were: OA 10.5%, 76.1%, and 13.4% versus
DA 19.7%, 72.7%, and 7.6% (p Z 0.513) (Fig. 3).Discussion
This study had two major findings. First, the patients with
mild to moderate hypertension who received an FDC
treatment with OA 20 mg/5 mg achieved greater SBP
reduction than those who received the DA (10 mg). Second,
among those using ABPM, the patients who received the
8-week treatment with the OA FDC also achieved a greater
SBP-lowering effect. Both treatments were well tolerated.dipine Double amlodipine p
71
3 52.5  13.1 0.590
61 0.641
5 73.6  13.9 0.971
163.3  8.6 0.404
110.6  28.4 0.437
13.5  4.1 0.549
1 0.82  0.83 0.413
4 200.9  39.9 0.238
4 152.4  14.9 0.997
92.1  7.3 0.286
Table 2 Changes in blood pressure after treatment between the two groups.
Treatment period Decrease in blood pressure p
Olmesartan/amlodipine (N Z 70) Double-dose amlodipine (N Z 71)
2 wk
Systolic 17.57  15.49 10.46  13.36 0.002
Diastolic 9.53  9.06 5.75  7.72 0.013
4 wk
Systolic 20.80  14.11 16.6  17.65 0.057
Diastolic 10.80  9.89 9.09  7.76 0.353
8 wk
Systolic 24.89  14.09 17.03  13.27 0.001
Diastolic 12.50  9.78 9.29  7.19 0.064
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worldwide. It is recognized as one of the most significant
risk factors for cardiovascular, cerebrovascular, and renal
disease. The World Health Organization reported that
suboptimal BP control ranks as the most common attribut-
able risk for death in the world [8]. The effect of hyper-
tension on cardiovascular events is greater for Asians than
for Caucasians, and the treatment of hypertension results
in greater cardiovascular risk reduction in Asian patients in
comparison with the Caucasian population [9,10]. Although
there was a significant improvement in the awareness,
treatment, and rate of control in Taiwan from 1993 to 2002,
the hypertension control rate was still low at only 21% in
men and 29% in women [11]. After 8 weeks of treatment in
our study, the BP control rate in those receiving the OA FDCA
B
Figure 2. Blood pressure changes after 8 weeks of treat-
ment. (A) Office BP. (B) Ambulatory blood pressure monitoring.was 67.1%, higher than the 53% attained by Caucasian
patients in a similar study [12].
Although amlodipine is the most frequently prescribed
antihypertensive agent in the world, clinical studies suggest
that 5 mg of amlodipine alone does not control the BP of
more than 50% of patients with hypertension. Although up-
titration of amlodipine may improve BP control rates, it
also increases the incidence of side effects that could
reduce patient compliance. Several international antihy-
pertensive treatment guidelines suggest using a combina-
tion therapy by adding an antihypertensive agent with
a synergistic and complementary mechanism of action to
help patients with hypertension attain their BP target
[4e6]. In addition, an FDC can be considered for first-step
treatment, provided the initial use of two drugs rather
than one is indicated [5,6]. In this study, patients with mild
to moderate hypertension who received an FDC treatment
with OA 20 mg/5 mg had greater SBP reduction than those
receiving DA (10 mg). After 2, 4, and 8 weeks of treatment,
the SBP reductions were 17.57, 20.80, and 24.89 mmHg,
respectively. Therefore, 71% and 84% of the maximal SBP
reductions after the 8-week treatment period were already
being observed after 2 and 4 weeks, respectively.
ABPM has become increasingly important for the
management of hypertension [13]. In addition to reducing
the white-coat effect, ABPM provides more reproducible BP
readings and represents more accurate predictors of future
cardiovascular risk than office BP measurement [14,15].
Among the patients using ABPM in this study, those with the
8-week OA FDC showed greater SBP-lowering effects than
those receiving DA. Furthermore, the ABPM SBP reduction
in our patients receiving the OA (20 mg/5 mg) FDC was
greater than for the patients in another study receiving
valsartan/amlodipine FDC (160 mg/5 mg) for 8 weeks where
their BPs were uncontrolled by amlodipine (5 mg) [16].
There were three limitations in our study. First, our
investigation had only a small number of patients. Second,
we did not have a placebo group because of the ethical
issues. Third, all of the participants did not agree to the
ABPM. However, our study results are consistent with
previous data in the Caucasian population.
In conclusion, we showed that using an OA FDC in the
Asian population provides more powerful SBP reduction, as
measured by both the office BP and the ABPM, than
a double-dose of amlodipine for patients with mild to
Table 3 Incidence of adverse events.
Adverse events Treatment Total
Olmesartan/
amlodipine
Double-dose
amlodipine
N 70 71 141
Blood and lymphatic system disorders Anemia 1 (1.4%) 0 (0.0%) 1 (0.7%)
Cardiac disorders Palpitations 2 (2.9%) 1 (1.4%) 3 (2.1%)
Ear and labyrinth disorders Cholesteatoma 1 (1.4%) 0 (0.0%) 1 (0.7%)
Eye disorders Borderline glaucoma 1 (1.4%) 0 (0.0%) 1 (0.7%)
Cataract 1 (1.4%) 0 (0.0%) 1 (0.7%)
Conjunctivitis (allergic) 1 (1.4%) 0 (0.0%) 1 (0.7%)
Lacrimation decreased 1 (1.4%) 0 (0.0%) 1 (0.7%)
Visual field defect 1 (1.4%) 0 (0.0%) 1 (0.7%)
Gastrointestinal disorders Constipation 0 (0.0%) 3 (4.2% ) 3 (2.1%)
Enteritis 1 (1.4%) 0 (0.0%) 1 (0.7%)
Gastroenteritis 1 (1.4%) 1 (1.4%) 1 (1.4%)
Nausea 0 (0.0%) 1 (1.4%) 1 (0.7%)
Periodontitis 0 (0.0%) 1 (1.4%) 1 (0.7%)
Reflux esophagitis 1 (1.4%) 1 (1.4%) 2 (1.4%)
Salivary gland calculus 1 (1.4%) 0 (0.0%) 1 (0.7%)
Sialoadenitis 1 (1.4%) 0 (0.0%) 1 (0.7%)
General disorders and
administration site conditions
Chest discomfort 1 (1.4%) 0 (0.0%) 1 (0.7%)
Chest pain 1 (1.4%) 0 (0.0%) 1 (0.7%)
Edema 11 (15.7%) 11 (15.5%) 22 (15.6%)
Edema peripheral 0 (0.0%) 1 (1.4%) 1 (0.7%)
Hepatobiliary disorders Liver disorder 1 (1.4%) 0 (0.0%) 1 (0.7%)
Infections and infestations Cellulitis streptococcal 0 (0.0%) 1 (1.4%) 1 (0.7%)
Helicobacter infection 0 (0.0%) 1 (1.4%) 1 (0.7%)
Upper respiratory tract infection 1 (1.4%) 1 (1.4%) 2 (1.4%)
Injury, poisoning, and
procedural complications
Contusion 0 (0.0%) 1 (1.4%) 1 (0.7%)
Foreign body 0 (0.0%) 1 (1.4%) 1 (0.7%)
Open wound 0 (0.0%) 2 (2.8%) 2 (1.4%)
Investigations Creatinine increased 1 (1.4%) 0 (0.0%) 1 (0.7%)
Non-HDL cholesterol increased 1 (1.4%) 0 (0.0%) 1 (0.7%)
Metabolism and nutrition disorders Hyperthyroidism 1 (1.4%) 0 (0.0%) 1 (0.7%)
Hyperuricemia 1 (1.4%) 0 (0.0%) 1 (0.7%)
Hypokalemia 1 (1.4%) 0 (0.0%) 1 (0.7%)
Musculoskeletal and connective
tissue disorders
Arthralgia 0 (0.0%) 2 (2.8%) 2 (1.4%)
Chondromalacia 0 (0.0%) 1 (1.4%) 1 (0.7%)
Gout 1 (1.4%) 1 (1.4%) 2 (1.4%)
Intervertebral disc disorder 1 (1.4%) 0 (0.0%) 1 (0.7%)
Musculoskeletal disorder 0 (0.0%) 1 (1.4%) 1 (0.7%)
Musculoskeletal stiffness 0 (0.0%) 1 (1.4%) 1 (0.7%)
Neck pain 1 (1.4%) 0 (0.0%) 1 (0.7%)
Tendinitis 1 (1.4%) 0 (0.0%) 1 (0.7%)
Neoplasms benign, malignant,
and unspecified
Benign neoplasm of skin 1 (1.4%) 1 (1.4%) 2 (1.4%)
Nervous system disorders Dizziness 2 (2.9%) 4 (5.6%) 6 (4.3%)
Headache 0 (0.0%) 1 (1.4%) 1 (0.7%)
Vertigo 0 (0.0%) 1 (1.4%) 1 (0.7%)
Vertigo positional 0 (0.0%) 1 (1.4%) 1 (0.7%)
Psychiatric disorders Anxiety 1 (1.4%) 0 (0.0%) 1 (0.7%)
Insomnia 0 (0.0%) 1 (1.4%) 1 (0.7%)
Sleep disorder 0 (0.0%) 2 (2.8%) 2 (1.4%)
Renal and urinary disorders Calculus urinary 0 (0.0%) 1 (1.4%) 1 (0.7%)
Nocturia 0 (0.0%) 1 (1.4%) 1 (0.7%)
Respiratory, thoracic, and
mediastinal disorders
Bronchitis 1 (1.4%) 0 (0.0%) 1 (0.7%)
Dyspnea 1 (1.4%) 0 (0.0%) 1 (0.7%)
Nasopharyngitis 0 (0.0%) 1 (1.4%) 1 (0.7%)
(continued on next page)
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Table 3 (continued )
Adverse events Treatment Total
Olmesartan/
amlodipine
Double-dose
amlodipine
N 70 71 141
Skin and subcutaneous
tissue disorders
Dermatophytosis 0 (0.0%) 1 (1.4%) 1 (0.7%)
Rash papular 0 (0.0%) 1 (1.4%) 1 (0.7%)
Surgical and medical procedures Promotion of wound healing 1 (1.4%) 0 (0.0%) 1 (0.7%)
HDL Z high-density lipoprotein.
Figure 3. Lower-leg edema between the two groups.
270 T.-H. Lin et al.moderate hypertension after the failure of amlodipine
monotherapy.
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